Literature DB >> 16940533

Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.

Donald N Forthal1, Gary Landucci, Kelly Stefano Cole, Marta Marthas, Juan C Becerra, Koen Van Rompay.   

Abstract

Although antibodies can prevent or modulate lentivirus infections in nonhuman primates, the biological functions of antibody responsible for such effects are not known. We sought to determine the role of antibody-dependent cell-mediated virus inhibition (ADCVI), an antibody function that inhibits virus yield from infected cells in the presence of Fc receptor-bearing effector cells, in preventing or controlling SIVmac251 infection in rhesus macaques (Macaca mulatta). Using CEMx174 cells infected with simian immunodeficiency virus mac251 (SIVmac251), both polyclonal and monoclonal anti-SIV antibodies were capable of potent virus inhibition in the presence of human peripheral blood mononuclear cell (PBMC) effector cells. In the absence of effector cells, virus inhibition was generally very poor. PBMCs from healthy rhesus macaques were also capable of mediating virus inhibition either against SIVmac251-infected CEMx174 cells or against infected, autologous rhesus target cells. We identified both CD14(+) cells and, to a lesser extent, CD8(+) cells as the effector cell population in the rhesus PBMCs. Finally, pooled, nonneutralizing SIV-antibody-positive serum, shown in a previous study to prevent infection of neonatal macaques after oral SIVmac251 challenge, had potent virus-inhibitory activity in the presence of effector cells; intact immunoglobulin G, rather than F(ab')(2), was required for such activity. This is the first demonstration of both humoral and cellular ADCVI functions in the macaque-SIV model. ADCVI activity in nonneutralizing serum that prevents SIV infection suggests that ADCVI may be a protective immune function. Finally, our data underscore the potential importance of Fc-Fc receptor interactions in mediating biological activities of antibody.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940533      PMCID: PMC1563916          DOI: 10.1128/JVI.02746-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.

Authors:  D N Forthal; G Landucci; E S Daar
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.

Authors:  K S Cole; M Alvarez; D H Elliott; H Lam; E Martin; T Chau; K Micken; J L Rowles; J E Clements; M Murphey-Corb; R C Montelaro; J E Robinson
Journal:  Virology       Date:  2001-11-10       Impact factor: 3.616

4.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons.

Authors:  T W Orlikowsky; Z Q Wang; A Dudhane; G E Dannecker; D Niethammer; G P Wormser; M K Hoffmann; H W Horowitz
Journal:  J Infect Dis       Date:  2001-10-02       Impact factor: 5.226

6.  Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; M Piatak; T Parks; L Li; R Kiser; V Coalter; B Fisher; B M Flynn; S Czajak; V M Hirsch; K A Reimann; J E Schmitz; J Ghrayeb; N Bischofberger; M A Nowak; R C Desrosiers; D Wodarz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

Authors:  Clarisa Buckner; Leoned G Gines; Cheryl J Saunders; Lucia Vojtech; Indresh Srivastava; Agegnehu Gettie; Rudolph Bohm; James Blanchard; Susan W Barnett; Jeffrey T Safrit; Leonidas Stamatatos
Journal:  Virology       Date:  2004-03-01       Impact factor: 3.616

9.  Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.

Authors:  L Jean Patterson; Nina Malkevitch; David Venzon; Joel Pinczewski; Victor Raúl Gómez-Román; Liqun Wang; V S Kalyanaraman; Phillip D Markham; Frank A Robey; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Activation of monocytic cells through Fc gamma receptors induces the expression of macrophage-inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES.

Authors:  Nieves Fernández; Marta Renedo; Carmen García-Rodríguez; Mariano Sánchez Crespo
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

View more
  63 in total

1.  A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.

Authors:  Diego A Vargas-Inchaustegui; Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

3.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

Review 4.  Is developing an HIV-1 vaccine possible?

Authors:  Barton F Haynes; Hua-Xin Liao; Georgia D Tomaras
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

5.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

6.  DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge.

Authors:  Margherita Rosati; Cristina Bergamaschi; Antonio Valentin; Viraj Kulkarni; Rashmi Jalah; Candido Alicea; Vainav Patel; Agneta S von Gegerfelt; David C Montefiori; David J Venzon; Amir S Khan; Ruxandra Draghia-Akli; Koen K A Van Rompay; Barbara K Felber; George N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-28       Impact factor: 11.205

7.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Authors:  Gregory Q Del Prete; Jeremy Smedley; Rhonda Macallister; Gregg S Jones; Bei Li; Jillian Hattersley; Jim Zheng; Michael Piatak; Brandon F Keele; Joseph Hesselgesser; Romas Geleziunas; Jeffrey D Lifson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-09-09       Impact factor: 2.205

9.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

10.  Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

Authors:  Cherie T Ng; J Pablo Jaworski; Pushpa Jayaraman; William F Sutton; Patrick Delio; LaRene Kuller; David Anderson; Gary Landucci; Barbra A Richardson; Dennis R Burton; Donald N Forthal; Nancy L Haigwood
Journal:  Nat Med       Date:  2010-10-03       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.